Transplantation Proceedings
Volume 36, Issue 9 , Pages 2525-2531 , November 2004

Update on liver transplantation using cyclosporine

References 

  1. Klempnauer J , Schrem H , Becker T , et al.  Liver transplantation today . Transplant Proc . 2001;33:3433
  2. Provencher SJ , Demers C , Bastien MC , et al.  Effect of cyclosporine A on cytochrome P-450-mediated drug metabolism in the partially hepatectomized rat . Drug Metab Dispos . 1999;27:449
  3. Schrem H , Klempnauer J , Borlak J . Liver-enriched transcription factors in liver function and development. Part I: the hepatocyte nuclear factor network and liver-specific gene expression . Pharmacol Rev . 2002;54:129
  4. Alvira LG , Herrera N , Salas C , et al.  Influence of cyclosporine on graft regeneration and function after liver transplantation: trial in pigs . Transplant Proc . 2002;34:315
  5. Mueller AR , Platz KP , Blumhardt G , et al.  The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506? . Clin Transplant . 1995;9:176
  6. Everson GT . Impact of immunosuppressive therapy on recurrence of hepatitis C . Liver Transpl . 2002;8(10 suppl 1):S19
  7. Gordon RD , Shaw BW Jr , Iwatsuki S , et al.  Indications for liver transplantation in the cyclosporine era . Surg Clin North Am . 1986;66:541
  8. Calne RY . Cyclosporine and liver transplantation . Mt Sinai. J Med . 1987;54:465
  9. Starzl TE , Iwatsuki S , Shaw BW Jr , et al.  Liver transplantation in the ciclosporin era . Prog Allergy . 1986;38:366
  10. Thomson AW , Bonham CA , Zeevi A . Mode of action of tacrolimus (FK506): molecular and cellular mechanisms . Ther Drug Monit . 1995;17:584
  11. Henry ML . Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles . Clin Transplant . 1999;13:209
  12. Dunn CJ , Wagstaff AJ , Perry CM , et al.  Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation . Drugs . 2001;61:1957
  13. Jorgensen KA , Koefoed-Nielsen PB , Karamperis N . Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus . Scand J Immunol . 2003;57:93
  14. Hemenway CS , Heitman J . Calcineurin. Structure, function, and inhibition . Cell Biochem Biophys . 1999;30:115
  15. Mascarell L , Truffa-Bachi P . New aspects of cyclosporin a mode of action: from gene silencing to gene up-regulation . Mini Rev Med Chem . 2003;3:205
  16. Blankenship JR , Steinbach WJ , Perfect JR , et al.  Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs . Curr Opin Investig Drugs . 2003;4:192
  17. Frei U . Overview of the clinical experience with Neoral in transplantation . Transplant Proc . 1999;31:1669
  18. Shah MB , Martin JE , Schroeder TJ , et al.  The evaluation of the safety and tolerability of two formulations of cyclosporine: neoral and sandimmune. A meta-analysis . Transplantation . 1999;67:1411
  19. European FK506 Multicentre Liver Study Group . Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection . Lancet . 1994;344:423
  20. The US Multicenter FK506 Liver Study Group . A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation . N Engl J Med . 1994;331:1110
  21. Starzl TE , Todo S , Demetris AJ , et al.  Tacrolimus (FK506) and the pharmaceutical/academic/regulatory gauntlet . Am J Kidney Dis . 1998;31(6 suppl 1):S7
  22. Timmermann W , Erhard J , Lange R , et al.  A randomised trial comparing the efficacy and safety of tacrolimus with microemulsified cyclosporine after liver transplantation . Transplant Proc . 2002;34:1516
  23. Dunn SP . Neoral monitoring 2 hours post-dose and the pediatric transplant patient . Pediatr Transplant . 2003;7:25
  24. Levy G , Burra P , Cavallari A , et al.  Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2) . Transplantation . 2002;73:953
  25. Jain A , Reyes J , Kashyap R , et al.  Long-term survival after liver transplantation in 4,000 consecutive patients at a single center . Ann Surg . 2000;232:490
  26. Parra Cid T , Conejo Garcia JR , Carballo Alvarez F , et al.  Antioxidant nutrients protect against cyclosporine A nephrotoxicity . Toxicology . 2003;189:99
  27. Oettinger-Barak O , Machtei EE , Peled M , et al.  Cyclosporine A- induced gingival hyperplasia pemphigus vulgaris: literature review and report of a case . J Periodontol . 2000;71:650
  28. Marchetti P , Navalesi R . The metabolic effects of cyclosporin and tacrolimus . J Endocrinol Invest . 2000;23:482
  29. Montori VM , Basu A , Erwin PJ , et al.  Posttransplantation diabetes: a systematic review of the literature . Diabetes Care . 2002;25:583
  30. Gijtenbeek JM , van den Bent MJ , Vecht CJ . Cyclosporine neurotoxicity: a review . J Neurol . 1999;246:339
  31. Bechstein WO . Neurotoxicity of calcineurin inhibitors: impact and clinical management . Transpl Int . 2000;13:313
  32. Wijdicks EF . Neurotoxicity of immunosuppressive drugs . Liver Transpl . 2001;7:937
  33. Schlitt HJ , Barkmann A , Boker KH , et al.  Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study . Lancet . 2001;357:587
  34. Lerut JP , Ciccarelli O , Mauel E , et al.  Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study . Transpl Int . 2001;14:420
  35. Rolles K , Davidson BR , Burroughs AK . A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin . Transplantation . 1999;68:1195
  36. Asberg A . Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients . Drugs . 2003;63:367
  37. Paoletti R , Corsini A , Bellosta S . Pharmacological interactions of statins . Atheroscler Suppl . 2002;3:35
  38. Gruer PJ , Vega JM , Mercuri MF , et al.  Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin . Am J Cardiol . 1999;84:811
  39. Lassila M . Interaction of cyclosporine A and the renin-angiotensin system; new perspectives . Curr Drug Metab . 2002;3:61
  40. Breidenbach T , Hoffmann MW , Becker T , et al.  Drug interaction of St John's wort with cyclosporin . Lancet . 2000;355:1912
  41. Tsunoda SM , Harris RZ , Christians U , et al.  Red wine decreases cyclosporine bioavailability . Clin Pharmacol Ther . 2001;70:462
  42. Bauer S , Stormer E , Johne A , et al.  Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients . Br J Clin Pharmacol . 2003;55:203
  43. Hermann M , Asberg A , Reubsaet JL , et al.  Intake of grapefruit juice alters the metabolic pattern of cyclosporin A in renal transplant recipients . Int J Clin Pharmacol Ther . 2002;40:451
  44. Halloran PF , Helms LM , Kung L , et al.  The temporal profile of calcineurin inhibition by cyclosporine in vivo . Transplantation . 1999;68:1356
  45. Wonigeit K , Kohlhaw K , Winkler M , et al.  Cyclosporine monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity . Transplant Proc . 1990;22:1305
  46. Keown PA . New concepts in cyclosporine monitoring . Curr Opin Nephrol Hypertens . 2002;11:619
  47. Kahan BD , Keown P , Levy GA , et al.  Therapeutic drug monitoring of immunosuppressant drugs in clinical practice . Clin Ther . 2002;24:330
  48. Levy GA . New strategies to optimize clinical outcomes with cyclosporine in liver transplantation . Gastroenterol Hepatol . 2002;25:289
  49. Nashan B , Cole E , Levy G , et al.  Clinical validation studies of Neoral C(2) monitoring: a review . Transplantation . 2002;73(9 suppl):S3
  50. Levy G , Thervet E , Lake J , et al.  Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group (2002). Patient management by Neoral C(2) monitoring: an international consensus statement . Transplantation . 2002;73(9 suppl):S12
  51. Kelly DA . Strategies for optimizing immunosuppression in adolescent transplant recipients: a focus on liver transplantation . Paediatr Drugs . 2003;5:177
  52. Mazariegos GV , Salzedas AA , Jain A , et al.  Conversion from cyclosporin to tacrolimus in pediatric liver transplant recipients . Paediatr Drugs . 2001;3:661
  53. Cooney GF , Dunn SP , Sommerauer J , et al.  Improved cyclosporine bioavailability in black pediatric liver transplant recipients after administration of the microemulsion formulation . Liver Transplant Surg . 1999;5:112
  54. Dunn S , Falkenstein K , Cooney G . Neoral C2 monitoring in pediatric liver transplant recipients . Transplant Proc . 2001;33:3094
  55. Tendron A , Gouyon JB , Decramer S . In utero exposure to immunosuppressive drugs: experimental and clinical studies . Pediatr Nephrol . 2002;17:121
  56. Prevot A , Martini S , Guignard JP . In utero exposure to immunosuppressive drugs . Biol Neonate . 2002;81:73
  57. Bar Oz B , Hackman R , Einarson T , et al.  Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis . Transplantation . 2001;71:1051
  58. Nashan B . Early clinical experience with a novel rapamycin derivative . Ther Drug Monit . 2002;24:53
  59. Nashan B . Review of the proliferation inhibitor everolimus . Expert Opin Investig Drugs . 2002;11:1845
  60. Eisen HJ , Tuzcu EM , Dorent R , et al.  Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients . N Engl J Med . 2003;349:847

PII: S0041-1345(04)01189-3

doi: 10.1016/j.transproceed.2004.10.023

Transplantation Proceedings
Volume 36, Issue 9 , Pages 2525-2531 , November 2004

Article Tools